Binding of MAR-DNA elements by mutant p53: Possible implications for its oncogenic functions

Journal of Cellular Biochemistry

Volumn 62, Issue 2, 1996, Pages 172-180

  Deppert, Wolfgang ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

chromatin structure; differentiation; nuclear matrix; recombination; replication; transcriptional activation

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

CANCER GENETICS; CARCINOGENESIS; CELL NUCLEUS MATRIX; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; REVIEW;

ANIMALS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MUTATION; ONCOGENES; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029827731     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P     Document Type: Review

References (42)

1. Bakalkin G, Yakovleva T, Selivanova G, Magnusson KP, Szekely L, Kiseleva E, Klein G, Terenius L, Wiman KG (1994): p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 91:413-417.
2. Bakalkin G, Selivanova G, Yakovleva T, Kiseleva E, Kashuba E, Magnusson KP, Szekely L, Klein G, Terenius L, Wiman KG (1995): p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res 23:362-369.
3. Berezney R (1991): The nuclear matrix: A heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 47:109-123.
4. Bode J, Schlake T, Ríos-Ramírez M, Mielke C, Stengert M, Kay V, Klerth-Wirth D (1995): Scaffold/matrix-attached regions (S/MARs): Structural properties creating transcriptionally active loci. In Jeon KW and Berezney R (eds): "Structural and Functional Organization of the Nuclear Matrix." Int Rev Cytol 162A:389-453.
5. Boulikas T (1995): Chromatin domains and prediction of MAR sequences. In Jeon KW and Berezney R (eds): "Structural and Functional Organization of the Nuclear Matrix." Int Rev Cytol 162A:279-388.
6. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994): Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355.
7. Cox LS, Lane DP (1995): Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. Bioessays 17:501-508.
8. Deppert W (1993): p53: Oncogene, tumor suppressor, or both? In Wagener C, Neumann S (eds): "Molecular and Cell Biological Methods in the Diagnosis of Malignant Diseases." Berlin, Heidelberg: Springer Verlag, pp 27-39.
9. Deppert W (1994a): Functional analysis of tumor suppressor p53. In Schmitt H, Graeff H, Kindermann H, Jänicke F, Genz T, Lampe B (eds): "Prospects of Diagnosis and Treatment of Breast Cancer." Amsterdam, New York, Oxford: Elsevier, pp 11-22.
10. Deppert W (1994b): The yin and yang of p53 in cellular proliferation. Cancer Biol 5:187-202.
11. Deppert W, Haug M (1986): Evidence for free and metabolically stable p53 protein in nuclear subfractions of simian virus 40-transformed cells. Mol Cell Biol 6:2233-2240.
12. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T (1992): A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 70:631-645.
13. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993): Gain of function mutations in p53. Nature Genet 4:42-46.
14. Dutta A, Ruppert JM, Aster JC, Winchester E (1993): Inhibition of DNA replication factor RPA by p53. Nature 365:79-82.
15. Eliyahu D, Michalovitz D, Oren M (1985): Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158-160.
16. Foord OS, Bhattacharya P, Reich Z, Rotter V (1991): A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res 19:5191-5198.
17. Gasser SM, Laemmli UK (1987): A glimpse at chromosomal order. Trends Genet 3:16-22.
18. Herbomel P (1990): From gene to chromosome: Organisation levels defined by the interplay of transcription and replication in vertebrates. New Biol 39:937-945.
19. Hinds P, Finlay C, Levine AJ (1989): Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-746.
20. Kaczmarek L, Ferguson B, Rosenberg M, Baserga R (1986): Induction of cellular DNA synthesis by purified adenovi-rus E1A proteins. Virology 152:1-10.
21. Lane DP (1992): Cancer: p53, guardian of the genome. Nature 358:15-16.
22. Lee S, Elenbaas B, Levine A, Griffith J (1995): p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
23. Lin J, Teresky AK, Levine AJ (1995): Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10:2387-2390.
24. Marx J (1993): How p53 suppresses cell growth. Science 262:1644-1645.
25. Milner J (1995): Flexibility: The key to p53 function? Trends Biochem Sci 20:49-51.
26. Milner J, Medcalf EA (1991): Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
27. Mosner J, Mummenbrauer T, Bauer C, Szakiel G, Grosse F, Deppert W (1995): Negative feedback regulation of wildtype p53 biosynthesis. EMBO J 14:4442-4449.
28. Müller B, Paulsen D, Deppert W (in press): Specific binding of MAR/SAR DNA elements by mutant p53. Oncogene.
29. Mummenbrauer T, Janus F, Müller B, Wiesmüller L, Deppert W, Grosse F (submitted): p53 protein exhibits 3′ to 5′ exonuclease activity.
30. Oberosler P, Hloch P, Ramsperger U, Stahl H (1993): p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBOJ 12:2389-2396.
31. Oren M (1994): Relationship of p53 to the control of apoptotic cell death. Cancer Biol 5:221-227.
32. Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V (1988): p53 increases experimental metastatic capacity of murine carcinoma cells. Mol Cell Biol 8:2078-2081.
33. Polack A, Feederle R, Klobeck G, Hörtnagel K (1993): Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells. EMBO J 12:3913-3920.
34. Shaulsky G, Goldfinger N, Rotter V (1991): Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 51:5232-5237.
35. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994): Multifactorial analysis of p53 alterations in human cancer: A review. Int J Cancer 57:1-9.
36. Steinmeyer K, Deppert W (1988): DNA binding properties of murine p53. Oncogene 3:501-507.
37. Stenger EJ, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P, Hough PVC, Mastrangelo IA (1994): p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J 13:6011-6020.
38. Stürzbecher HW, Donzelmann B, Henning W, Knippschild U, Buchhop S (in press): p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J.
39. Vogelstein B, Kinzler KW (1992): p53 function and dysfunction. Cell 70:523-526.
40. Weißker S, Müller B, Homfeld A, Deppert W (1992): Specific and complex interactions of murine p53 with DNA. Oncogene 7:1921-1932.
41. Xia F, Wang F, Wang Y-H, Tsang N-M, Yandell DW, Kelsey KT, Liber HL (1995): Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 55:12-15.
42. Zerrahn J, Deppert W, Weidemann D, Patschinsky T, Richards F, Milner J (1992): Correlation between conformational phenotype and subcellular localization of mouse p53. Oncogene 7:1371-1381.